Groowe Groowe / Newsroom / RARE
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

RARE News

Ultragenyx Pharmaceutical Inc.

Pomerantz LLP Issues Important Reminder to Ultragenyx Pharmaceutical Inc. Investors – RARE

accessnewswire.com
RARE

Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

globenewswire.com
RARE

INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit - RGRD Law

globenewswire.com
RARE

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines – RARE

globenewswire.com
RARE

Holzer & Holzer, LLC Reminds Investors of April 6, 2026 Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against BlackRock TCP Capital Corp. (TCPC), Mereo BioPharma Group plc (MREO), POMDOCTOR LIMITED (POM), and Ultragenyx Pharmaceutical Inc.

globenewswire.com
TCPC MREO POM RARE

RARE Shareholder Alert: Ultragenyx Pharmaceutical Inc. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm

prnewswire.com
RARE

RARE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

accessnewswire.com
RARE

Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

accessnewswire.com
RARE

ROSEN, A TOP RANKED LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RARE

accessnewswire.com
RARE

Pomerantz LLP Issues Important Reminder to Investors in Ultragenyx Pharmaceutical Inc. of Class Action Filing – RARE

accessnewswire.com
RARE